{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:18:11Z","timestamp":1788430691566,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"DOI":"10.7759\/cureus.115703","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:47:56Z","timestamp":1788428876000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential"],"prefix":"10.7759","author":[{"given":"Aisha","family":"Quadir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshna","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Jad Allah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabah Shakeel","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyanram N","family":"Botsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23946","article-title":"Efficacy and safety of semaglutide 2.4\u2009mg according to antidepressant use at baseline: a post hoc subgroup analysis","volume":"32","author":"Kushner RF","year":"2024","unstructured":"Kushner RF, Fink-Jensen A, Frenkel O, McGowan B, Goldman B, Overvad M, Wadden T. Efficacy and safety of semaglutide 2.4\u2009mg according to antidepressant use at baseline: a post hoc subgroup analysis. Obesity (Silver Spring). 2024, 32:273-80. 10.1002\/oby.23946","journal-title":"Obesity (Silver Spring)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy SL","year":"2024","unstructured":"McElroy SL, Guerdjikova AI, Blom TJ, Mori N, Romo-Nava F. Liraglutide in obese or overweight individuals with stable bipolar disorder. J Clin Psychopharmacol. 2024, 44:89-95. 10.1097\/JCP.0000000000001803","journal-title":"J Clin Psychopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden TA","year":"2024","unstructured":"Wadden TA, Brown GK, Egebjerg C, et al.. Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials. JAMA Intern Med. 2024, 184:1290-300. 10.1001\/jamainternmed.2024.4346","journal-title":"JAMA Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1629157","article-title":"Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial","volume":"16","author":"Fang W","year":"2025","unstructured":"Fang W, Li Z, Xu J, Zhao J, Zhu H, Wang H. Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial. Front Endocrinol (Lausanne). 2025, 16:1629157. 10.3389\/fendo.2025.1629157","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70122","article-title":"Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT","volume":"34","author":"Wadden TA","year":"2026","unstructured":"Wadden TA, Oquendo MA, Kushner RF, Cao D, Karanikas CA, Kechter A, Murphy MA. Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT. Obesity (Silver Spring). 2026, 34:565-78. 10.1002\/oby.70122","journal-title":"Obesity (Silver Spring)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.20230226","article-title":"Glucagon-like peptide 1: an introduction and possible implications for neuropsychiatry","volume":"36","author":"L\u00f3pez-Ojeda W","year":"2024","unstructured":"L\u00f3pez-Ojeda W, Hurley RA. Glucagon-like peptide 1: an introduction and possible implications for neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2024, 36:A4-86. 10.1176\/appi.neuropsych.20230226","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100916","article-title":"Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: a randomized clinical trial","volume":"7","author":"Badulescu S","year":"2026","unstructured":"Badulescu S, Gill H, Shah H, et al.. Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: a randomized clinical trial. Med. 2026, 7:100916. 10.1016\/j.medj.2025.100916","journal-title":"Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre RS","year":"2024","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Kwan AT. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024, 23:47-55. 10.1080\/14740338.2023.2295397","journal-title":"Expert Opin Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre RS","year":"2025","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, et al.. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae). J Affect Disord. 2025, 369:922-7. 10.1016\/j.jad.2024.10.062","journal-title":"J Affect Disord"},{"key":"ref10","unstructured":"FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. (2026). Accessed. May 2, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-requests-removal-suicidal-behavior-and-ideation-warning-gluc...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001, 16:606-13. 10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer RL","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006, 166:1092-7. 10.1001\/archinte.166.10.1092","journal-title":"Arch Intern Med"},{"key":"ref14","article-title":"ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision, 2nd ed","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision, 2nd ed. World Health Organization, Geneva; 2004."},{"key":"ref15","article-title":"International Classification of Diseases, Ninth Revision, Basic Tabulation List with Alphabetic Index","author":"World Health Organization","year":"1978","unstructured":"World Health Organization. International Classification of Diseases, Ninth Revision, Basic Tabulation List with Alphabetic Index. World Health Organization, Geneva; 1978."},{"key":"ref16","article-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells GA","year":"2000","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute (OHRI), Ottawa, ON; 2000."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-06","article-title":"Systematic reviews of etiology and risk","author":"Moola S","year":"2024","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (ed): Joanna Briggs Institute (JBI), Adelaide, Australia; 2024. 10.46658\/JBIMES-24-06"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi R","year":"2024","unstructured":"De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, Taquet M. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine. 2024, 74:102726. 10.1016\/j.eclinm.2024.102726","journal-title":"EClinicalMedicine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study","volume":"67","author":"Hurtado I","year":"2024","unstructured":"Hurtado I, Robles C, Peir\u00f3 S, Garc\u00eda-Sempere A, Sanf\u00e9lix-Gimeno G. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia. 2024, 67:2471-80. 10.1007\/s00125-024-06243-z","journal-title":"Diabetologia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius E","year":"2024","unstructured":"Kornelius E, Huang JY, Lo SC, Huang CN, Yang YS. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep. 2024, 14:24433. 10.1038\/s41598-024-75965-2","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2025-005840","article-title":"Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study","volume":"14","author":"Kuzucan A","year":"2026","unstructured":"Kuzucan A, Tran V, Jones JT, et al.. Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study. BMJ Open Diabetes Res Care. 2026, 14:e005840. 10.1136\/bmjdrc-2025-005840","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080679","article-title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study","volume":"388","author":"Shapiro SB","year":"2025","unstructured":"Shapiro SB, Yin H, Yu OH, Rej S, Suissa S, Azoulay L. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. 2025, 388:e080679. 10.1136\/bmj-2024-080679","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-026-03619-y","article-title":"GLP-1 receptor agonists and risk of suicide or suicide attempts - A nationwide cohort and self-controlled case series study","volume":"31","author":"Stanislaus C","year":"2026","unstructured":"Stanislaus C, Winther-Jensen M, Stanislaus S, Osler M, Coello K, Vinberg M. GLP-1 receptor agonists and risk of suicide or suicide attempts - A nationwide cohort and self-controlled case series study. Mol Psychiatry. 2026, 31:5316-22. 10.1038\/s41380-026-03619-y","journal-title":"Mol Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(26)00014-3","article-title":"Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study","volume":"13","author":"Taipale H","year":"2026","unstructured":"Taipale H, Taylor M, L\u00e4hteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. Lancet Psychiatry. 2026, 13:327-35. 10.1016\/S2215-0366(26)00014-3","journal-title":"Lancet Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7326\/M24-0329","article-title":"Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes : a target trial emulation study","volume":"177","author":"Tang H","year":"2024","unstructured":"Tang H, Lu Y, Donahoo WT, et al.. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes : a target trial emulation study. Ann Intern Med. 2024, 177:1004-15. 10.7326\/M24-0329","journal-title":"Ann Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 receptor agonist use and risk of suicide death","volume":"184","author":"Ueda P","year":"2024","unstructured":"Ueda P, S\u00f6derling J, Wintzell V, et al.. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024, 184:1301-12. 10.1001\/jamainternmed.2024.4369","journal-title":"JAMA Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie Y","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025, 31:951-62. 10.1038\/s41591-024-03412-w","journal-title":"Nat Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1128387","article-title":"The potential antidepressant effect of antidiabetic agents: new insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase","volume":"14","author":"Battini V","year":"2023","unstructured":"Battini V, Van Manen RP, Gringeri M, et al.. The potential antidepressant effect of antidiabetic agents: new insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Front Pharmacol. 2023, 14:1128387. 10.3389\/fphar.2023.1128387","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/nu16152438","article-title":"Association between symptoms of depression and generalised anxiety disorder evaluated through PHQ-9 and GAD-7 and anti-obesity treatment in Polish adult women","volume":"16","author":"Witaszek T","year":"2024","unstructured":"Witaszek T, K\u0142oda K, Mastalerz-Migas A, Babicki M. Association between symptoms of depression and generalised anxiety disorder evaluated through PHQ-9 and GAD-7 and anti-obesity treatment in Polish adult women. Nutrients. 2024, 16:2438. 10.3390\/nu16152438","journal-title":"Nutrients"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15864","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: a comprehensive analysis of the global pharmacovigilance database","volume":"26","author":"Kim TH","year":"2024","unstructured":"Kim TH, Lee K, Park S, et al.. Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: a comprehensive analysis of the global pharmacovigilance database. Diabetes Obes Metab. 2024, 26:5183-91. 10.1111\/dom.15864","journal-title":"Diabetes Obes Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret AC","year":"2025","unstructured":"Pierret AC, Mizuno Y, Saunders P, et al.. Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis. JAMA Psychiatry. 2025, 82:643-53. 10.1001\/jamapsychiatry.2025.0679","journal-title":"JAMA Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang W","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024, 30:168-76. 10.1038\/s41591-023-02672-2","journal-title":"Nat Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70415","article-title":"Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes","volume":"28","author":"Hooker SA","year":"2026","unstructured":"Hooker SA, Neugebauer RS, Schmittdiel JA, et al.. Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes. Diabetes Obes Metab. 2026, 28:2215-26. 10.1111\/dom.70415","journal-title":"Diabetes Obes Metab"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70393","article-title":"Mental health changes after 4\u2009months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0\u2009mg","volume":"28","author":"Kuckuck S","year":"2026","unstructured":"Kuckuck S, van Gerwen N, Oosterman JE, et al.. Mental health changes after 4\u2009months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0\u2009mg. Diabetes Obes Metab. 2026, 28:2095-104. 10.1111\/dom.70393","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/518137-impact-of-glucagon-like-peptide-1-receptor-agonists-on-mental-health-a-systematic-review-of-psychiatric-safety-and-antidepressant-potential","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:47:57Z","timestamp":1788428877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/518137-impact-of-glucagon-like-peptide-1-receptor-agonists-on-mental-health-a-systematic-review-of-psychiatric-safety-and-antidepressant-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.115703","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}